Spago Nanomedical AB (publ) (STO:SPAGO)

Market Cap	99.24M
Revenue (ttm)	6.73M
Net Income (ttm)	-32.18M
Shares Out	348.20M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,249
Average Volume	159,300
Open	0.3200
Previous Close	0.2850
Day's Range	0.3000 - 0.3500
52-Week Range	0.0918 - 0.4280
Beta	1.79
RSI	66.93
Earnings Date	Aug 21, 2025

About Spago Nanomedical AB

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPAGO

Financial Performance

In 2024, Spago Nanomedical AB's revenue was 6.65 million, an increase of 17.94% compared to the previous year's 5.64 million. Losses were -32.51 million, -23.01% less than in 2023.